P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US200200018 2	Abandoned CON is 13/617 988 (not yet published)	1/3/2002	Cytoplasm c transfer to de-differentiate recipient cells																				
US20020090722	Abandoned no CONs pending	7/11/2002	Pluripotent mammalian cells																				
US20020136709	Abandoned no CONs pending	9/26/2002	In itro-deri ed adult pluripotent stem cells and uses therefor	Nucleus Remodeling Inc.																			
US200201 2397	Abandoned CONs are US2005001 258 (US7736895) and US200 0072288	10/3/2002	Methods for altering ce l fate																				
US200300 976	Abandoned no CONs pending	3/6/2003	De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies	Ad anced Cell Technology (Worcester MA)																			
US20030211603	Abandoned no CONs pending	2003-11-13	Reprogramming cells for enhanced differentiation capaci y using pluripotent stem cells																				
US20030229908	USPN 7696 0	12/11/2003	Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic de elopment by genetic alteration of donor cells or by issue culture conditions	Ad anced Cell Technology	X			X		Blastocyst	Human cell into rabbit oocyte			Producing a nuclear transfer human/rabbit blastocyst by cross-species nuclear transfer								X (nuclear transfer)	Yes (claims more limited)
US200 0009595	USPN 7138275 (undergoing interpartes reexam 95/001 158)	1/15/200	Dedifferentiated programmable stem cells of monocytic origin and their production and use	Blasticon Biotechnologische Forschung GmbH Keil (DE)	X	X (pharmaceutical composition)	X			Programmable cell ability to differentiate into neuron glial endothelial adipocyte hepatocyte keratinocyte and insulin-producing cell	Monocyte			Cell line expresses the following antigens CD1 CD123 CD90 and CD135					X			X	
US200 0072288	USPN 7 9153	/15/200	Methods for altering ce l fate to genera e T-cells specific for an antigen of interest	Kyowa Hakko Kirin CO. LTD.	X			X			Fibroblast			Reprogramming a cell to express a T-cell receptor reacti e with an antigen of interest								X (uses cell extracts)	Yes (claims more limited)
US200 00723 3	Abandoned no CONs pending	200 -0 -15	Cell reprogramming																				
US200 0101962	Expressly abandoned CONs are US7138275 US7553660 US7553663 US7517686	5/27/200	Dedifferentiated programmable stem cells of monocytic origin and their production and use																				
US200 0120932	Abandoned no CONs pending	200 -06-2	In itro-deri ed adult pluripotent stem cells and uses therefor																				
US200 0199935	Abandoned CON 13/617 988 (not yet published)	10/7/200	Cytoplasm c transfer to de-differentiate recipient cells																				
US200 02 1838	Abandoned no CONs pending	200 -12-02	Stem cells																				
US2005001 258	USPN 7736895	1/20/2005	Methods for altering ce l fate	KIRIN PHARMA KABUSHIKI KAISHA	X			X		Neural-like cell	Fibroblast			Reprogramming using cell extracts from an ac i ated T cell neural precursor cell or embryonic stem cell	X			X				X (cell extract)	Yes (claims more limited)
US20050058628	Abandoned no CONs pending	2005-03-17	Nuclear reprogramming of cells for therapeutic use																				
US2005008 968	Abandoned no CONs pending	2005-0 -21	Tailor-made multifunctional stem cells and utilization thereof	Norio Nakatsuji (273-7 Iwakuranishigawaracho Sakyo-ku Kyoto JP)																			
US200501301	Abandoned no CONs pending	2005-06-16	Method of screening reprogramming factor reprogramming factor screened by the method method of us ng the																				
US200501 7652	Abandoned no CONs pending	2005-07-07	Cell deli ery system																				
US2005170506	Abandoned no CONs pending	2005-08-0	Therapeutic reprogramming hybrid stem cells and maturation	PrimeGen Biotech LLC (Ir ine CA US)																			
US20050210537	Abandoned no CONs pending	2005-09-22	Pluripotent mammalian cells																				
US20050221 83	USPN 7553663	10/6/2005	Dedifferentiated programmable stem cells of monocytic origin and their production and use	Blasticon Biotechnologische Forschung GmbH Keil (DE)		X				Hepatocyte-like cell	Monocyte	X (method of treating hepatocyte disorders)	X (in implantable ma eria)					X					
US20050233 7	USPN 7553660	10/20/2005	Dedifferentiated programmable stem cells of monocytic origin and their production and use	Blasticon Biotechnologische Forschung GmbH Keil (DE)	X					Hepatocyte-like cell				Cell expressing albumin and a membrane-associated CD1 surface antigen				X	X			X	
US20060078989	USPN 7517686	/13/2006	Dedifferentiated programmable stem cells of monocytic origin and their production and use	Blasticon Biotechnologische Forschung GmbH Keil (DE)	X			X		Dedifferentiated cell	Monocyte		X (implan able material)					X				X	
US20060110830	Abandoned CON 20080076176 pending	5/25/2006	De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies	Ad anced Cell Technology Inc. (Worcester MA US)																			

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US2006018272	Abandoned CON 20100261152 pending	8/17/2006	Method for expans on of stem cells																				
US20060188 91	Abandoned no CONs pending	2006-08-2	Use of nuclear material to therapeutically reprogram differentiated cells	PrimeGen Biotech LLC (Ir ine CA US)																			
US20060222636	Abandoned no CONs pending	2006-10-05	Compositions methods and kits relating to reprogramming adult differentia ed cells and production of embryonic stem cell-like cells	The Rockefeller Uni ersity																			
US20060252062	pending	11/9/2006	System and process for genetic and epigene ic treatment		X	X		X	X	See notes.	Foetal embryonic tissue or hematopoetic cell and oocyte extract	X (cancer treatment and cell repair process)	X	Treatment of cardiac renal bone dental desmodontal cartilaginous pancreatic hepatic ner e prostate hematopoietic immune pulmonary arterial retinal cutaneous dermal epidermal glandular tendon ascular spleen parathyroid suprarenal and/or digesti e and respiratory tracts				X	X			X	
US20070020759	Abandoned no CONs pending	2007-01-25	Therapeutic reprogramming of germ line stem cells	PrimeGen Biotech LLC (Ir ine CA US)																			
US20070025973	Abandoned no CONs pending	2007-02-01	Reprogramming of adult or neonic stem cells and methods of use																				
US20070032 7	USPN 7601699	2/8/2007	Production of reprogrammed cells with restored potential	NuPotential Inc. (Baton Rouge LA US)	X			X			Eukaryotic cell			Reprogramming method that decreases S-adenosylmethione to S-adenosylhomocysteine ratio or suppresses DNA methyltransferases							X (siRNA used to suppress expression)	X	Yes (claims more limited)
US20070087 37	Abandoned no CONs pending	2007-0 -19	Methods for reju enating cells in itro and n i o																				
US20070196918	Abandoned no CONs pending	2007-08-23	Reprogramming of adult human testicular stem cells to pluripotent germ-line stem cells																				
US200702 3610	Abandoned CON 20120083032 pending	10/18/2007	Embryonic Stem Cell Line and Method for Preparing the Same	Seoul National Uni ersity Industry Foundation (San -2 Boncheon-dong Gwanak-gu Seoul KR)																			
US20080076176	pending	3/27/2008	De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies	Ad anced Cell Technology Inc. (Worcester MA US)	X		X (withdrawn claim)	X		See notes.	See notes.			Reprogramming somatic cell with cytoplasm of pluripotent cell. Somatic cells include fibroblasts B cells T cells dendritic cells keratinocytes adipose ce ls epithelial cells epidermal cells chondrocytes cumulus cells neural cells glial cells astrocy es cardiac cells esophageal cells muscle cells melanocytes hematopoietic cells macrophages monocytes and mononuclear cells. Pluripotent cells include oocy es blastomeres inner cell mass cells embryonic cells morula-deri ed cells and teratoma cells.	X				X (currently withdrawn)			X (cell extracts)	
US20080089868	Abandoned no CONs pending	2008-0 -17	Retinal stem cell compositions and methods for prepar ng and using same	The Research Foundation of State Uni ersi y of New York (Albany NY US)																			
US20080112937	Abandoned no CONs pending	2008-05-15	Method of Producing Autologous Embrya	MEDISTEM LABORATORIES, NC. (Chandler, AZ, US)																			
US2008233610	pending	3/21/2008	SOMATIC CELL REPROGRAMMING	Wisconsin Alumni Research Foundation (Madison WI US)	X			X						Explicitly does not use KLF or c-myc	X					X	X dependent claims for retro iral ector		
US2008267930	Abandoned no CONs pending	2008-10-30	Biological Materials and Uses Thereof	The Uni ersity of Nottingham (Nottingham GB)																			
US2008027 91	USPN 796 01	11/6/2008	Screening Method for Somatic Cell Nuclear Reprogramming Substance	DAINIPPON SUMITOMO PHARMA CO. LTD. (OSAKA JP) Kyoto Uni ersity	X			X			Mouse cells											X (knock-in techniques)		Yes (claims narrower)
US2008280362	USPN 7682828	11/13/2008	Methods for reprogramming somatic cells	Whitehead Inst tute for Biomedical Research (Cambridge MA US)	X		X								X							X	X	
US200802931 3	pending	11/27/2008	Generation of human embryonc stem-like cells using intronic RNA		X			X		Pluripotent	Mammalian human cancerous somatic				X					X		X gene silencing)	
US20080299 5 8	USPN 7803920	12/ /2008	Gene Expressed Specif cally in Es Cells and utilization of the Same	DAINIPPON SUMITOMO PHARMA CO. LTD. (Osaka-shi JP)	X		X				Mouse or human embryonic stem cell												X	
US200900 7263	USPN 827810	2/19/2009	Nuclear reprogramming factor and induced pluripotent stem cells	KYOTO Uni ersity	X		X	X							X	X	X	X	X				X	
US200900687 2	USPN 80 8999	3/12/2009	Nuclear Reprogramming Factor	KYOTO Uni ersity	X		X	X							X	X	X	X	X				X	no cell claim
US20090092616	USPN 8071378	/9/2009	ZNF206 A No el Regulator of Embryonic Stem Cell Self-renewal and Pluripotency	Burnham Institute For Medical Research (La Jolla CA US)	X			X			Embryonic stem cell			Other markers are alkaline phosphatase SSEA- Tra-1-80 and Tra-1-60	X						X (retro irus)		Yes (claims narrower)
US20090137023	Abandoned no CONs pending	2009-05-28	Cytoplasm of Eukaryotic cells for reprogramming of somatic cells healing repairing and therapeutic applications	Casutt Brandon John (Las Vegas NV US)																			

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US20090191159	USPN 8211697	7/30/2009	Multipotent/pluripotent cells and methods	KYOTO Uni ersity	X		X	X		see notes for differentiated cells	see notes for source cells			Sources = skin fibroblasts PBM cells bone marrow-deri ed mononuclear cells endothelial cells smooth muscle cells skeletal muscle cells adipose cells Diff. cells = pancreatic beta cell a neural stem cell a dopaminergic neuron an oligodendrocyte a hepatocyte or a cardiac muscle cell.	X	X	X		X	X can be deli ered ia adeno	X can be deli ered by lenti or retro irus	X	Oct Klf and cytokine used. cMyc explicitly excluded. Not limited by cell type.
US20090191171	Abandoned no continuation	7/30/2009	Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination		X		X	X							X	X	X		X		X	X	
US200902031 1	pending	8/13/2009	Generation of tumor-free embryon c stem-like pluripotent cells using inducible recombinant RNA agents		X			X		Somatic	Stem cell				X					X		X	
US20090227032	pending	9/10/2009	Nuclear reprogramming factor and induced pluripotent stem cells	KYOTO Uni ersity	X		X	X						Requires Oct3/ K f and a Myc gene from c-Myc L-Myc and N-Myc (myc is a chimera)	X	X	X		X			X	
US200902 6875	pending	10/1/2009	Efficient method for nuclear reprogramming	KYOTO Uni ersity	X			X							X	X	X					X	
US20090252711	Abandoned no continuation	10/8/2009	Stem Cells And Methods Of Making And Using Stem Cells		X			X			see notes for source cells			Sources = adipose tissue stromal stem cell bone marrow stromal stem cell hematopoietic stem cell hair follicle stem cell neural stem cell muscle stem cell cord blood stem cell skin stem cell li er stem cell and pancreatic stem cell								X	
US20090253203	pending	10/8/2009	Reprogramming a Cell by Inducing a Pluriotent Gene Through Use of a Small	NuPotential Inc. (Baton Rouge LA US)	X			X						Reprogramming using small molecule inhibitors.	X				X			X	
US20090263357	Abandoned no CONs pending	2009-10-22	Therapeutic Reprogramming Hybrid Stem Cells and Maturation	PrimeGen Biotech LLC (I ine CA US)																			
US20090269763	Pending allowed awaiting issuance	10/29/2009	Reprogramming a cell by inducing a pluripotent gene through RNA interference	NuPotential Inc. (Baton Rouge LA US)	X			X						Reprogramming using shRNA constructs. Other pluripotent genes are Sox-2 and Nanog Surface markers are SSEA3 SSEA Tra-1-60 and Tra-1-81.	X				X			X	
US20090271335	Abandoned CON 13/585 380 (not yet published)	10/29/2009	Totipotent Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes	Ad anced Cell Technology Inc. (Alameda CA US)																			
US20090275032	pending	11/5/2009	Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator	NuPotential Inc. (Baton Rouge LA US)	X			X						Reprogramming using small molecule inhibitors. Other pluripotent genes are Sox-2 and Nanog Surface markers are SSEA3 SSEA Tra-1-60 and Tra-1-81.	X				X (currently withdrawn)			X	
US20090280096	pending	11/12/2009	PANCREATIC ENDOCRINE PROGENITOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS		X		X	X		see notes for differentiated cells		For diabetes pancreas		Diff. cells = pancreatic endocrine progenitor cells primiti e beta-islet cells					X			X	
US20090299763	pending	12/3/2009	METHODS OF CELL-BASED TECHNOLOGIES	iZumi Bio Inc.					X Ser ice for pro iding iPS cells					manipulating the sample o force expression of Oct Klf Myc	X	X	X					X	
US2009030 6 6	Expressly abandoned no continuaton	12/10/2009	Multipotent/Pluripotent Cells and Methods		X			X							X	X	X	X	X			X	
US20100003757	pending	1/7/2010	METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH	Cellular Dynamics Intl. Inc.	X		X	X		see notes for differentiated cells	see notes for source cells			Sources = fibroblast a keratinocyte a hematopoietic cell a mesenchymal cell a li er cell a stomach cell or a β cell mbryonic stem cell an nduced pluripotent stem cell a hematopoietic stem cell a neural stem cell a mesenchymal stem cell a hematopoietic progenitor an endoderm progenitor a pancreat c progenitor or an endothelial progen tor	X	X	X		X	X		X minimizes foreign iral DNA	
US20100008891	pending	1/1 /2010	Production of Pluripotent Cells Through Inhibition of Bright/Arid3a Function		X			X		Fat neuronal pancreatic hematopoietic muscle or endothelial cell phenotype	Bone marrow fibroblast spleen peripheral blood cell			Reprogramming cell using Bright/ARID3a inh bitor and leukemia inhibitory factor.				X		X		X	
US20100021 37	pending	1/28/2010	NEURAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS	The McLean Hospital Corporation Whitehead Inst tute for Biomedical Research	X		X	X		dopaminergic neurons	skin fibroblasts	Parkinson's therapy			X	X	X	X	X			X	
US201000 105	pending	2/18/2010	METHODS FOR THE PRODUCTION OF IPS CELLS	Cellular Dynamics Intl. Inc.	X		X Reprogramming ector	X			fibroblasts hematopoietic cells or mesenchymal cells				X	X	X			X extrachromosomal iral ector	X retro iral ector	X	
US20100062533	USPN 8058065	3/11/2010	Nuclear reprogramming factor and induced pluripotent stem cells	KYOTO UNIVERSITY	X			X							X	X	X					X	Method of prep PSC
US2010006253	pending	3/11/2010	INDUCIBLE LENTIVIRAL VECTORS FOR REPROGRAMMING SOMATIC CELLS	THE GENERAL HOSPITAL CORPORATION (Boston MA US) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge MA US)	X		X	X			fibroblast cells kerat nocytes				X	X	X		X		X	X	
US20100075 21	Abandoned CON is US200902 6875 (pending)	3/25/2010	Efficient method for nuclear reprogramming	Kyoto Uni ersity	X		X	X							X	X	X		X		X retro iral ector	X	
US20100093090	pending	/15/2010	METHOD AND KIT FOR EFFICIENT REPROGRAMMING OF SOMATIC CELLS	PEKING UNIVERSITY (BEIJING CN) BEIJING HUA YUAN BO CHUANG TECHNOLOGY CO. LTD. (BEIJING CN)	X		X	X							X	X	X		X			X	
US20100099189	Abandoned no CONs pending	2010-0 -22	Methods for Reju enating Cells In Vitro and In Vi o																				
US20100105100	Expressly abandoned no continuaton	/29/2010	MULTIPOTENT/PLURIPOTENT CELLS AND METHODS		X	X	X	X							X	X	X		X		X	X	
US20100120069	Expressly abandoned no continuaton	5/13/2010	MULTIPOTENT/PLURIPOTENT CELLS AND METHODS		X			X	Determine factors in caus ng pluripotency						X						X	X	
US20100135970	pending	6/3/2010	Methods for Reprogramming Adult Somatic Cells and Uses Thereof	Cari as St. Elizabeth Medical Center of Boston In (Boston MA US)	X	X (withdrawn)	X (withdrawn)	X	X (withdrawn)	Cardiomyocyte endothelial cell neuronal cell or adipocyte	Fibroblast	X (withdrawn)	X (wi hdrawn)	Reprogramming a cell using embryonic stem cell extract and culturing with BMP-2 retinoic acid dexamethasone insulin LIF or indomethacin. Cell may also express Nanog SCF SSEA1 and c-Kit.	X			X	X (withdrawn)			X (cell extract)	
US20100137202	pending	6/3/2010	COMPOSITIONS FOR REPROGRAMMING A CELL AND USES THEREFOR	Uni ersi y of Florida Research Foundation (Gaines ille FL US)	X	X		X		Cell with restored function (insulin generation)	Li er or pancreatic cell of diabetic subject	X		Contacting a cell with pdx-1 polypeptides to increase insulin								X	
US201001 031	pending (CON of US20080280362)	6/10/2010	METHODS FOR REPROGRAMMING SOM TIC CELLS		X			X							X							X	

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US201001 039	pending	6/10/2010	Pluripotency determining factors and uses thereof	The Uni ersity of Edinburgh (Edinburgh GB)	X			X		Pluripotent cell	Mouse or human somatic cell			Nanog				X		X	X		
US20100150889 US20100158868	Abandoned CON is 13/ 80 753 (not yet published) Abandoned no CONs pending	6/17/2010 2010-06-2	Polycistronic Vector For Human Induced Pluripotent Stem Cell Production Use of Fetal Cells for the Treatment of Genetic Diseases	THE UAB RESEARCH FOUNDATION Birmingham AL Kan Yuet W. (San Francisco CA US)	X		X	X							X	X	X		X	X	X	X	
US20100159 59	pending	6/2 /2010	PRODUCTION OF REPROGRAMMED CELLS WITH RESTORED	NUPOTENTIAL INC. (Baton Rouge LA US)	X			X						In ol es reducing the percentage of cytosines in DNA that are methylated								X	
US20100167 0	pending	7/1/2010	Methods of Reprogramming Animal Somatic Cells	ADVANCED CELL TECHNOLOGY INC. (Alameda CA US)	X			X						reprogramming d fferentiated somatic cell into undifferentiated stem cell by injecting the somatic cell into an oocyte from a different species to cause nuclear remodelling followed by transfer of the remodeled nucleus to the enucleated cytoplasm of an undifferentiated embryonic cell	X		X						
US20100172966	Abandoned no CONs pending	7/8/2010	Methods and compositions for cellular reprogramming				X	X						composition oligoribonucleotide double-stranded oligo or chimeric RNA/DNA oligo targeting nucleic ac d for long list of factors method reprogramming by administering oligo	X		X						
US2010018 051	pending	7/22/2010	METHODS OF GENERATING PLURIPOTENT CELLS FROM SOMATIC CELLS	THE GENERAL HOSPITAL CORPORATION (Boston MA US) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge MA US)	X			X						Transform cells that lack Nanog by RT-PCR solate clones	X	X	X				X	X	
US2010018 225	pending	7/22/2010	USE OF A CELLULAR EXTRACT FOR A MITOTIC REMODELING OF CHROMOSOMES	centre National de la Recherche Scientifique (Paris FR)	X			X						method for mitotic remodeling of chromosomes using M-phase Xenopus egg extract and EGTA									
US2010018 227	USPN 8268620	7/22/2010	PLURIPOTENT STEM CELLS OBTAINED BY NON-VIRAL REPROGRAMMING	Wisconsin Alumni Research Foundation (Madison WI US)	X			X						Requires Oct and Sox2 dependent claims include LIN28 NANOG c-Myc and KLF .	X					X			
US2010021001	Abandoned no CONs pending	8/19/2010	Nuclear reprogramming factor and induced pluripotent stem cells	Kyoto Uni ersity (Kyoto JP)	X			X							X	X	X	X				X	
US20100216236	USPN 8129187	8/26/2010	Nuclear reprogramming factor and induced pluripotent stem cells	Kyoto Uni ersity (Kyoto JP)	X			X							X	X	X					X	Method of prep PSC. Uses cytokine
US20100221827	USPN 8071369 (CON of US20080280362)	9/2/2010	COMPOSITIONS FOR REPROGRAMMING SOMATIC	Whitehead Inst tute	X		X								X							X	
US20100227396	pending	9/9/2010	Embryonic Stem Cell-Like Cells	Seoul National Uni ersity Industry Foundation (Seoul KR)	X		X	X			see notes for source cells			o ary bone marrow peripheral blood umbilical cord blood amniotic fluid brain blood essel skele al muscle epithelia of skin or gastrointestinal tract comea dental pulp of tooth retina li er spleen or pancreas	X							X	
US2010023380	pending	9/16/2010	GENERATION OF PLURIPOTENT STEM CELLS USING RECOMBINANT PROTEINS	The Scripps Research Institute (La Jolla CA US)	X		X Protein	X						Transcription factor protein to facilitate transport across cell membrane	X	X	X		X			X focuses on peptide deli ery	
US201002 0090	Expressly abandoned no continuaton	9/23/2010	METHODS AND PLATFORMS FOR DRUG DISCOVERY	iZumi Bio Inc. (South San Francisco CA US)	X				Use iPS ce ls for testing compounds													X	
US201002 0132	pending	9/23/2010	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS		X			X						method of injecting nucleus from differentiated cell into enucleated egg acti ating the egg and allowing to grow to the 2 cell stage transferring the nucleus from the 2 cell egg to an enucleated 2-cell stage embryo									
US20100261152	pending	10/1 /2010	Method for expans on of stem cells		X			X		Erythroid megakaryocytic lymphoid and granulocytic lineage	Placental tissue hematopoietic stem cell							X				X	
US201002671 1	pending	10/21/2010	CHEMICAL APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS	THE SCRIPPS RESEARCH INSTITUTE (LA JOLLA CA US)	X		X	X						Use cassette to express Oct and Klf expose cell to TGFbeta/ALK5 inhibitor to make iPS cells	X	X	X					X	
US20100272695	pending	2010-10-28	CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED REPROGRAMMED CELLS		X	X	X	X						differentiated cells deri ed from genetica ly reprogrammed cells and Rho-kinase inhib tor method for producing insulin from reprogrammed cells									
US20100279 0	pending	11/ /2010	METHOD OF NUCLEAR REPROGRAMMING		X		X	X						Non- ral ectors encoding Oct Klf and Sox genes but no myc and a ector with myc only	X	X	X		X	X	X	X	
US20100285589	pending	11/11/2010	GENERATION OF PLURIPOTENT CELLS FROM FIBROBLASTS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland CA US)	X		X	X						Retro ral ector encoding Oct Sox2 Klf c/n-myc Nanog	X	X	X		X		X retro ral ector	X	
US20100303775	pending	12/2/2010	Generation of Genetically Corrected Disease-free Induced Pluripotent Stem Cells	THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (LA JOLLA CA US) THE CENTER OF REGENERATIVE MEDICINE (BARCELONA ES)	X		X	X				Administer iPS cells to mammal for tissue repair		Fix a diseased differentiated cell then create iPS cell with Oct Sox2 Klf and c-Myc	X	X	X		X			X	
US2010030 89	pending	2010-12-02	METHODS AND COMPOSITIONS FOR HOMOLOGOUS RECOMBINATION IN HUMAN	THE GENERAL HOSPITAL CORPORATION (Boston MA US)	X		X							human stem cell with GSKbeta inibitor	X	X	X						
US20100310525	pending	2010-12-09	WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC	Whitehead Inst tute for Biomedical Research (Cambridge MA US)	X	X						X		reprogramming somatic cell with agent that modifies a Wnt pathway	X	X							
US20100311170	pending	2010-12-09	METHOD FOR REPROGRAMMING DIFFERENTIATED CELLS					X		somatic cell neural stem cell embryonic fibroblast or thymocyte				exposing fusing or co-culturing a differentiated cell to pluripotent cell preteated with or expressing Wnt/beta-catenin pathway acti ator					X				
US20100311171	pending	12/9/2010	VECTORS FOR GENERATING PLURIPOTENT STEM CELLS AND METHODS OF PRODUCING PLURIPOTENT STEM CELLS USING THE SAME	NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Tokyo JP)	X		X	X						Sendai irus used to hold Oct3/ Sox2 Klf and c-Myc	X	X	X		X	X (transient infection with Sendai irus)			
US20100317711 US20100330063	Abandoned no CONs pending Abandoned no CONs pending	2010-12-16 2010-12-30	STEM-LIKE CELLS AND METHOD FOR REPROGRAMMING ADULT MAMMALIAN SOMATIC CELLS STEM-LIKE CELLS METHOD FOR DE-DIFFERENTIATING MAMMALIAN SOMATIC CELLS INTO STEM-LIKE CELLS AND METHOD FOR DIFFERENTIATING	GLIAMED INC. (Dobbs Ferry NY US) GLIAMED INC. (New York NY US)																			
US20100330677	pending	12/30/2010	Impro ed Reprogramming of Mammal an Cells and Cells Obtained	Cambridge Enterprise Limited (Cambridge GB)	X		X	X						Reprogram with acti ator of Stat3 optionally a GSK3 inhibitor	X	X	X	X	X	X	X	X	
US20110003365	pending	2011-01-06	METHOD OF PREPARING INDUCED PLURIPOTENT STEM CELLS DEPRIVED OF REPROGRAMMING GENE	KYOTO UNIVERSITY (Kyoto-shi JP)	X			X						iPS cell ha ing an expression ector with loxP flanking a reprogramming gene treat cell with Cre						X		X	

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US2011002081	Abandoned no CONs pending	1/27/2011	METHODS AND COMPOSITIONS FOR SELECTION OF STEM CELLS	IPIERIAN INC. (SOUTH SAN FRANCISCO CA US)	X		X	X							X	X	X		X			X	
US20110027881	pending	2011-02-03	PRODUCTION METHOD OF IMMUNE CELLS	St. Marianna Uni ersity School of Medicine (Kawasaki-shi JP)	X			X		immune cells e.g. mature B cells				method of producing immune cells by generating pluripotent stem cells from immune cells and differentiating into immune cells by coculture with OP9 cells	X	X	X						
US201100283 5	pending	2011-02-03	METHODS TO CHARACTERIZE CELL REPROGRAMMING AND USES THEREOF	CORNING INCORPORATED	X				X					method comprising adhering an undifferentiated cell on a biosensor culturing unt l checkpoint(s) obtaining primary profile(s) for markers at each checkpo nt									
US20110028537	USPN 8183038	2/3/2011	SOMATIC CELL REPROGRAMMING	Wisconsin Alumni Research Foundation (Madison WI US)	X		X							Requires SOX2 OCT- NANOG and LIN28 linked to a promoter	X					X	X		
US20110033936	pending	2011-02-10	CANINE iPS CELLS AND METHOD OF PRODUCING SAME	KYOTO UNIVERSITY (Kyoto-shi JP)	X			X		canine somatic cell fibroblast adipose				transfect canine somatic cell with retro ıral ector (Oct3/ Sox2 Klf c-Myc) culture cell with kinase inhibitors FGF and LIF	X	X	X				X		
US2011003 536	USPN 8133731	2/10/2011	CONTROLLING THE POTENTIAL OF PRIMATE NEURAL STEM CELLS BY REGULATING PAX6	WISCONSIN ALUMNI RESEARCH FOUNDATION	X		X	X		Neural stem cells					X				X		X (lenti ıral ec or)	X	Method of creating neural SC by introducing Pax6. Oct Klf Myc cytokines not cited
US20110039332	pending	2/17/2011	HUMAN PLURIPOTENT STEM CELLS INDUCED FROM UNDIFFERENTIATED STEM CELLS DERIVED FROM A HUMAN POSTNATAL TISSUE		X		X	X			neonatal skin or a blood essel deri ed from the umbilical cord				X	X	X	X	X			X	
US20110039338	pending	2/17/2011	METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS	KYOTO UNIVERSITY Kyoto-shi JP	X			X						Increase transfection efficiency with hypoxic conditions	X	X	X					X	
US201100 1857	pending	2/2 /2011	FIBROBLAST DERIVED STEM CELLS	The Trustees of Columbia Uni ersi y In The City of New York (New York NY US) The Research Foundation of State Uni ersi y of New York (Albany NY US) Worchester Polytechnic Institute (Worcester MA US)	X	X	X	X			Fibroblas s	Cardiac repair	Cells n scaffold for cardiac repair	Diff. cells = cardiomyocy e adipocyte neuron glia cell endothel al cell keratinocyte hepatocyte or islet cell				X	X			X	
US201100 961	pending	2/2 /2011	Generation of Induced Pluripotent Stem Cells from Cord Blood	Salk Institute for Biological Studies (La Jolla CA US) Center of Regenerati e Medicine (Barcelona ES)	X		X	X			cord blood stem cell				X	X	X		X			X	
US20110053166	pending	3/3/2011	STEM CELL EXPRESSION CASSETTES	The Hospital for Sick Children (Toronto ON CA)	X		X	X										X	X			X	
US201100532	pending	3/3/2011	NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS		X		X							Use atoxic portions of toxins to induce de-differentiation	X	X	X			X		X	
US20110059526	pending	2011-03-10	REPROGRAMMING A CELL BY INDUCING A PLURIPOTENT GENE THROUGH USE OF AN HDAC MODULATOR	NUPOTENTIAL INC. (Baton Rouge LA US)	X		(withdrawn)	X						reprogramming a cell by exposing it to small molecules that inhibit the acti ity expression or both of HDAC and a methyltransferase or histone demethylase exoanding the population of pluripotent cell	X			X	(withdrawn)				
US20110061118	pending	3/10/2011	VECTORS AND METHODS FOR GENERATING VECTOR-FREE INDUCED PLURIPOTENT STEM (IPS) CELLS USING SITE-SPECIFIC RECOMBINATION	Helmholtz Zentrum Munchen (Neuherberg DE)	X		X	X							X	X	X			X	X		
US20110065103	pending	2011-03-17	USE OF RNA FOR REPROGRAMMING SOMATIC CELLS		X		X	X	X	somatic cell fibroblast				method of producing cells with s em cell characteris ics by introduction of RNA assay ro identify factors useful for reprogramming with RNA kit for producing cells RNA for inducing de elopment of stem cell characteristics in a cell	X	X	X	X	X				
US20110065192	Abandoned CON is 2012008032	3/17/2011	Embryonic stem cell line and method for preparing the same	H Bion Co. Ltd. (Seoul KR)																			
US20110076678	pending	2011-03-31	REPROGRAMMING OF SOMATIC CELLS		X			(withdrawn)						purified isolated plur potent mammalian cells (not ESCs) from reprogrammed somatic cells that differentiate into endoderm mesoderm ectoderm in SCID mice no selectable marker method of identifying reprogramming agent by determining wherher agent changes resistance to DNA methylation	X	X	X	X	X	X		X	
US20110081719	pending	2011-0 -07	Substantially pure human retinal progenitor forebrain progenitor and retinal pigment epi helium cell cultures and methods of making the same	Wisconsin Alumni Research Foundation (Madison WI US)	X		X			human neuroepithelial lineage (retinal progenitor forbrain progenitor ret nal pigmented epithelium	ES cells			Substantially pure culture of human neuroepithelial lineage cells method of separating neuroepithelial lineage cells by progenitor cell type					X				
US20110088107	pending	2011-0 -1	COMPOSITIONS AND METHODS FOR DERIVING OR CULTURING PLURIPOTENT CELLS		X			X						modifying pluripotency state of cell by causing it to express Klf and/or Klf2 culturing with GSK3 and MAPK inhibitors and STAT3 acti ator and culturing the cell		X			X				
US20110091 33	pending	2011-0 -21	TREATMENT USING REPROGRAMMED MATURE ADULT CELLS			X	X	X			whole blood bone marrow neuronal tissue muscle tissue epidermis or dermis	X		method of replen shing arget cells in a patient by reprogramming of committed cells with an antibody that engages a receptor that mediates capture recognition or presentation of an antigen on the committed cells and administering reprogrammed cells to patient									
US20110091 3	pending	2011-0 -21	AUGMENTATION OF CELL THERAPY EFFICACY INCLUDING TREATMENT WITH ALPHA 1-3 FUCOSYLTRANSFERASE	AMERICA STEM CELL INC. (Carlsbad CA US)		X	X					X		pro iding population of stem cells progenitor cells neutrophils macrophages and/or T–cells that ha e been contacted with an agent that modifies at least one surface molecule to enhance select n-mediated binding					X				

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US2011010 125	pending	2011-05-05	EPISOMAL REPROGRAMMING WITH CHEMICALS		X		X	X		somatic cell e.g. fibroblast keratinocyte hematopoietic cell mesenchymal cell adipose ce l endothelial cell neural cell muscle mammary li er kidney skin digesti e tract cell culmulus gland or pancreatic islet cell				method of producing iPS cells using somatic cells comptis ng an extra-chromosomal genetic element that expresses one or more reprogramming factors culturing with GSK3 MEK and TGFbeta receptor inhibitors			X			X			
US2011010 805	pending	5/5/2011	Pluripotent Stem Cells	CENTOCOR ORTHO BIOTECH INC. Horsham PA	X		X	X			Amn otic fluid-deri ed cells											X	
US20110110899	pending	5/12/2011	Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells	SCRIPPS RESEARCH INSTITUTE (LA JOLLA CA US)	X		X	X							X	X	X		X			X	
US20110117653	pending	5/19/2011	METHOD FOR PRODUCTION OF PLURIPOTENT STEM CELL	Takara Bio Inc. (Otsu-shi Shiga JP)	X			X							X	X	X					X	
US201101361 5	pending	2011-06-09	METHODS FOR PROMOTING FUSION AND REPROGRAMMING OF SOMATIC CELLS	THE JOHNS HOPKINS UNIVERSITY (Baltimore MD US)	X			X						method of reprogramming somat c cell by treating with agent(s) that induces de-differentiation wherein the agents are a his one methyltransferase inhibitor or a histone demethylase					X				
US201101 3397	pending	2011-06-16	RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS		X			X						method of reprogramming a cell from a first differentiated to a second differentiated state us ng modified mRNA encoding reprogramming factor(s)	X	X	X	X					
US201101 3 15	pending	6/16/2011	REPROGRAMMING NORMAL AND CANCEROUS HUMAN CELL LINES INTO HUMAN INDUCED POLURIPOTENT STEM CELLS BY CO-ELECTROPORATION WITH LIVING XENOPUS LAEVIS FROG		X		X	X							X							X	
US201101 3 36	pending	2011-06-16	COMPOSITIONS AND METHODS FOR REPROGRAMMING EUKARYOTIC CELLS		X			X						method of changing state of differentiation of a somatic cell using mRNA molecules encoding iPS cell induction factor(s) where mRNA molecules ha e been treated with Rnase III are polyadenylated and o er 98% are capped	X	X	X	X					
US201101 3 1	pending	2011-06-16	Methods of Reprogramming Animal Somatic Cells		X			X						method for reprogramm ng a somatic cell to undifferentiated stem cell by injecting somatic cell(s) into an oocyte allowing remodeling of the nucleus of the somatic cell and expression of genes of an undifferentiated cell and transferring the remodeled nucleus to an enucleated undifferent ated stem cell	X		X	X					
US20110151 7	pending	6/23/2011	METHOD TO PRODUCE INDUCED PLURIPOTENT STEM (IPS) CELLS FROM NON-EMBRYONIC HUMAN CELLS	CHILDREN'S MEDICAL CENTER CORPORATION (BOSTON MA US)	X		X	X							X	X	X		X		X	X	
US2011015 518	pending	6/23/2011	GENERATION OF INDUCED PLURIPOTENT STEM (iPS) CELLS	MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.	X		X	X			ectodermal cells neural stem cells				X	X	X		X			X	
US20110159592	pending	6/30/2011	COMPOSITION FOR REPROGRAMMING SOMATIC CELLS TO GENERATE INDUCED PLURIPOTENT STEM CELLS COMPRISING Oct IN COMBINATION WITH Bmi1 OR ITS UPSTREAM REGULATOR AND METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS USING THE SAME	KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION Seoul KR	X		X	X							X			X	X	X	X uses MMV re ro inus	X	
US20110171183	pending	7/1 /2011	Markers of Induced Pluripotent Stem Cells	AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (Singapore SG)	X		X	X											X			X	
US20110171185	pending	7/1 /2011	Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof		X		X	X						treating a somatic cell or nucleus of somatic cell with at least one reprogramming factor to con ert the cell or nucleus in o a mult potent or pluripotent cell or nucleus	X	X	X						
US20110177557	pending	7/21/2011	Fusion Protein and Use Thereof	Life & Brain GmbH (Bonn DE)	X		X	X						a fusion protein comprising 6 to 12 basic amino acids and at least one transcription factor may also include hydrophobic amino acids method of using the fus on protein to generate induced pluripotent cells or for the differentiation of plur potent cells	X	X	X						
US20110189137	pending	8/ /2011	METHOD FOR GENERATION AND REGULATION OF IPS CELLS AND COMPOSITIONS THEREOF	Sanford-Burnham Medical Research Institute (La Jolla CA US)	X		X	X			Fibroblast				X	X	X		X			X	
US20110190152	pending	8/ /2011	PLURIPOTENCY ASSOCIATED EPIGENETIC FACTOR		X			X						method of contro ling the phenotype of a cell by modulat ng the expression or acti ity of an ESET/SETDB1 polypeptide or homologue thereof									
US20110201110	pending	8/18/2011	EFFICIENT METHOD FOR ESTABLISHING INDUCED PLURIPOTENT STEM CELLS	GIFU UNIVERSITY (Gifu-shi JP) KYOTO UNIVERSITY (Kyoto-shi JP)				X		dental pulp stem cells				method of producing iPS cells by bringing nuclear reprogramming substances into con act wi h dental pulp stem cells	X	X	X						
US2011021727	pending	9/8/2011	METHODS FOR PRODUCTION AND USES OF MULTIPOTENT PLURIPOTENT DIFFERENTIATED AND DISEASE-RESISTANT CELL POPULATIONS		X		X	X	X	X		X		method of obtaining self-renewing mulipotent or pluripotent cells by introduc ng or o erexpressing in cells nucleic acid(s) or protein(s) corresponding to Oct Nanog Sox2 and/or PRR Numb	X			X	X				

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US20110223669	pending	9/15/2011	METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS	KYOTO UNIVERSITY (Kyoto-shi JP)	X			X						inpro ing the efficiency of establishing iPS cell by contacting isolated somatic cell w th siRNA or shRNA (or DNA encoding) that nhibits p53 producing iPS cells with nuclear reprogramming substances and siRNA or shRNA to p53	X	X	X						
US20110223670	pending	9/15/2011	ETS2 AND MESP1 GENERATE CARDIAC PROGENITORS FROM FIBROBLASTS	Texas Heart Institute (Houston TX US) Uni ersity of Houston (Houston TX US) The Texas A&M Uni ersity System (College Station TX US)	X			X		fibroblast				method of prepar ng cardiac progenitor cell by transducing a fibroblast cell with ETS2 and Mesp1									
US201102319	pending	9/22/2011	B CELL-DERIVED IPS CELLS AND APPLICATION THEREOF	RIKEN (Wako-shi JP)	X			X		B cell				contacting B cell with reprogramming factors (including Oct3/ Sox2 Klf and optionally c-Myc but not C/EBPalpha and Pax5 expression inhibiting substances wherein the resulting cloned cell has rearranged immunoglobulin genes possesses pluripotency and replication competence	X	X	X						
US20110236362	pending	9/29/2011	NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM	RIKEN (Wako-shi JP)	X	X	X	X		NKT cell fibroblast		X		cloned cell obtained from contacting with reprogramming factors a somatic cell ha ing the alpha chain region of the T cell antigen receptor gene rearranged to uniform Valpha-Jalpha in an NKT cell receptor-specific way	X	X	X	X	X				
US2011023689	pending	9/29/2011	SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS	IMMUNE DISEASE INSTITUTE INC. (Boston MA US)	X			X			Fibroblast				X	X	X				X	X	
US20110236966	pending	9/29/2011	SINGLE LENTIVIRAL VECTOR SYSTEM FOR INDUCED PLURIPOTENT (IPS) STEM CELLS DERIVATION	BOSTON MEDICAL CENTER CORPORATION (Boston MA US)	X		X								X	X	X		X		X lenti irus ector	X	
US20110236978	pending	9/29/2011	REPROGRAMMING CELLS TOWARD A PLURIPOTENT STATE	Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e. V. (Munchen DE)	X			X						reprogramming of cells by introducing mRNA molecules (Ron n Oct Klf Sox2 Nanog and or TERT) and culturing the cells	X	X							
US201102 3898	pending	10/6/2011	SOMATIC CELL-DERIVED PLURIPOTENT CELLS AND METHODS OF USE THEREFOR	The Uni ersity of Louis ille Research Foundation Inc. (Louis ille KY US)	X		X	X			Fibroblast				X	X		X	X			X	
US201102 566	pending	10/6/2011	Enhanced efficiency of induced pluripotent stem cell generation		X			X						producing iPS cells by contacting somatic cells with minicircle DNA ector(s) encoding a plurality of reprogramming factors	X	X	X		X				
US20110250692	pending	10/13/2011	METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM	KYOTO UNIVERSITY (KYOTO JP)	X			X							X					X	X	X	
US20110256626	pending	10/20/2011	METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS WITH HIGH EFFICIENCY AND INDUCED POLURIPOTENT STEM CELLS PROUCED THEREBY	SEOUL NATIONAL UNIVERSITY HOSPITAL (Seoul KR)	X		X	X										X	X			X	
US20110258713	pending	10/20/2011	COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC	VIVOSCRIPT INC. (Costa Mesa CA US)		X	X					X		treating a disease by administrat on of transducible material comprising an effector domain	X	X	X						
US20110258715	pending	10/20/2011	ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION	THE UNIVERSITY OF TOKYO (BUNKYO-KU JP)		X		X				X		method of producing a target organ in a li ing non-human animal that lacks the organ at a particular stage by preparing iPS cell from a different animal transplanting the cell into a blastocyst de eloping the fertilized egg in a surrogate and obtaining the organ from an animal in the resulting litter.									
US20110263001	Abandoned no continuation (CON is 13/571 1 1 not yet published)	10/27/2011	Compositions and Methods for Engineering Cells	Life Technologies Corporation (Carlsbad CA US)			X							Isolated nucleic acid molecule comprising an OriP site EBNA1 gene one or more att recombination sites and at least one selectable marker may include a reprogramming genetissue-specofoc gene or de elopmental gene may comprise a irus	X	X	X						
US2011026877	pending	11/3/2011	PREPARATION OF STEM CELLS WITH REPROGRAMMED CELL SIGNALLING A METHOD OF PRODUCING THE PREPARATION AND A METHOD OF USE THEREOF		X	X	X	X				X		stem cell preparation with altered cell signalling with implanted protein or pharmaceutical preparat on pre iously encapsulated into biodegradable nanocontainers with a preset period of biodegradation in the mammal directly in the mammal method of producing treatment of disease injury tumors of brain and spinal cord and tumors of other organs					X				
US20110275105	pending	11/10/2011	Methods of inducing pluripotency		X		X	X							X	X	X		X			X	
US20110275157	pending	11/10/2011	COMPOSITION FOR REPROGRAMMING SOMATIC CELLS TO GENERATE INDUCED PLURIPOTENT STEM CELLS COMPRISING Bmi1 AND LOW MOLECULAR WEIGHT SUBSTANCE AND METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS USING	KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (Seoul KR)	X		X	X						reprogramming somatic cells to ebryonic stem cell-like cells with Bmi1 and at least one set of inhibitors (MEK/ERK and GSK inhibitors G9a HMTase and DMNT inhibitors and histone deacetylase inhibitor)					X				X
US201102808 2	pending	11/17/2011	METHODS OF REPROGRAMMING CELLS	PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (Cambridge MA US)	X	X	X	X			endoderm	X		reprogramming endoderm origin cell by increasing expression of at least two of Pdx1 Ngn3 or MafA to reprogram to exhibit pancreatic beta cell characteristics further comprises increasing expression of NeuroD Nkx2.2 Nkx6.1 Pax Pax6 and/or Isl1 treatment of diabetes						X			
US20110281281	USPN 80 8675	11/17/2011	INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD	iPierian Inc. (South San Francisco CA US)	X			X			nucleated blood cells				X	X	X			X			method for gen iPSC
US20110286978	pending	11/2 /2011	Genetically Intact Induced Pluripo ent Cells Or Transdifferent ated Cells And Methods For The Production Thereof		X		X	X	X			X		con erting somat c cell or nucleus into multipotent or pluripotent cell or nucleus or different cell fate or lineage by treating with at least one reprogramming factor factor may be pro ided by secretion by a source cell	X	X	X		X			protein	

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US20110287536	pending	11/2 /2011	SIMPLIFIED METHOD FOR PARTIAL GENETIC AND EPIGENETIC REPROGRAMMING OF CELLS		X			X						reju enation of cells while remaining differentiated and immunologically autologous to tissue from which they were deri ed eg using anti-HP1 siRNA									
US20110300111	pending	12/8/2011	GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS	CEDARS-SINAI MEDICAL CENTER (Los Angeles CA US)	X		X	X				Cardiac therapy			X	X						X	
US20110300627	pending	12/8/2011	DEDIFFERENTIATION AND REPROGRAMMING OF CELLS		X			X			amnion			reprogrammed amnion-deri ed cells amnion ep thelial cells or amnion-deri ed mulipotent progenitor cells method of reprogramming	X	X	X		X			X	
US20110302665	pending	12/8/2011	NON-HUMAN MAMMALS WITH T OR B CELLS HAVING PREDEFINED SPECIFICITY				X	X						producing a non-human mammal from a T or B cell (to produce a mammal with T or B cells with predefined specificity) the mammal so produced									
US20110305713	pending	12/15/2011	METHODS AND COMPOSITIONS TO ENHANCE VACCINE EFFICACY BY REPROGRAMMING REGULATORY T CELLS	Medical College of Georgia Research Institute Inc (Augusta GA US)	X	X		X	X					method of reprogramming a regulatory T cell to pro-inflammatory T-hlper-like phenotype using a accine and inhibitor of the IDO pathway may be done in a subject								X	
US20110306516	pending	12/15/2011	METHODS FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS	THE NEW YORK STEM CELL FOUNDATION (New York NY US)	X		X	X		fibroblast				producing iPSC from adult f broblast by contacting fibriblast with a reprogramming composition culturing sorting based on cell surface express on of CD13NEG SSEA POS and Tra-1-60POS may include inhibitors of TGFbeta MAPK/ERK GSK3 pathway HDAC inhibitors PDK1 acti ators mitochondrial oxidation modulators glycolytic metabolism modulators and/or HIF pathway acti ators	X	X	X		X			X	
US20110311 9	pending	12/22/2011	METHODS OF REPROGRAMMING RENAL CELLS	Tel HaShomer Medical Research Infrastructure and Ser ices Ltd. (Ramat-Gan IL)	X			X		renal cells	kidney			Method of reprogramming a renal cell using Oct/Klf/Nanog and a renal gene (Six2 Osr1 Pax2 Sal1 cited 1)	X	X						X	
US20110318830	pending	12/29/2011	COMPOSITIONS AND METHODS FOR RE-PROGRAMMING AND RE-DIFFERENTIATING CELLS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland CA US)	X		X	X						Chimeric proteins that can b nd genes for reprogramming Oct Sox2 Klf c Myc Lin28 Nanog	X		X					X	
US20120009158	pending	1/12/2012	VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES	THE GENERAL HOSPITAL CORPORATION (Boston MA US)	X		X	X		Ventricular cardiomyocy e	fibroblast a skin fibroblast or cardiac fibroblast or a cardiomyocyte				X	X	X	X	X			X	
US20120009601	Expressly abandoned no continuaton	1/12/2012	METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS	THE GENERAL HOSPITAL CORPORATION (Boston MA US)	X		X		Assess risk of cancerous transformation of an iPS cell						X			X		X (chemical transformation)		X	
US20120009676	pending	1/12/2012	GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD		X			X		blood cells	blood				X	X	X	X		X			
US20120021019	pending	1/26/2012	CARDIAC STEM CELL POPULATIONS FOR REPAIR OF CARDIAC TISSUE	UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA (Rome IT)	X		X				cardiac tissue												
US20120021517	pending	1/26/2012	Bacterial Mediated Deli ery of Nuclear Protein Into Pluripotent and Differentiated Cells	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (GAINESVILLE FL US)	X		X	X							X	X	X			X (bacterial protein deli ery)			
US20120021519	pending	1/26/2012	EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS	PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (Cambridge MA US)	X			X						Small molecule used n the absence of Sox2	X	X	X					X	
US20120028351	pending	2/2/2012	GENERATION AND MAINTENANCE OF STEM CELLS	THE SCRIPPS RESEARCH INSTITUTE (LAJOLLA CA US)	X			X							X	X		X	X			X	
US20120028821	pending	2/2/2012	PROGRAMMING AND REPROGRAMMING OF CELLS		X		X							Expression ector	X	X	X			X			
US201200 63 6	pending	2/23/2012	SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC MODIFIED RNAS AND USES THEREOF	IMMUNE DISEASE INSTITUTE INC. (Boston MA US)			X	X						Syn hetic RNAs that encode Oct Sox Nanog c-Myc etc.	X	X	X			X			
US20120052505	pending	3/1/2012	METHODS FOR DETECTING EMBRYONIC STEM CELLS INDUCED PLURIPOTENT STEM CELLS OR CELLS UNDERGOING REPROGRAMMING TO PRODUCE INDUCED PLURIPOTENT STEM CELLS	NEW YORK UNIVERSITY (New York NY US) Agency for Science Technology and Research (A*STAR) (Singapore SG) NATIONAL UNIVERSITY OF SINGAPORE (Singapore SG)	X				X					Method for detecting ES cells with small molecule									
US20120058562	pending	3/8/2012	REPROGRAMMING IMMORTALIZED B CELLS		X			X		B cell	blood			Method for making iPS from immortalized B cells								X	
US2012006 0 8	pending	3/15/2012	TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A	OPKO CuRNA LLC (Miami FL US)	X			X						Methods for modulating reprogramming factors in patients with antisense oligonucleo ides						X			
US20120070 19	pending	3/22/2012	METHOD OF ALTERING THE DIFFERENTIATIVE STATE OF A CELL AND COMPOSITIONS	INTERNATIONAL STEM CELL CORPORATION (Oceanside CA US)	X			X						Expression cassettes with tagged proteins (Oct Sox Klf etc.)	X	X	X			X			
US20120070896	pending	3/22/2012	METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS AND METHOD FOR CULTURING THE SAME	Kyoto Uni ersity (Kyoto JP)	X			X						Co-culture somatic cell transformed with factors along with non-transformed cell	X	X						X	
US20120083032	pending	/5/2012	EMBRYONIC STEM CELL LINE AND METHOD FOR PREPARING	H. BION CO. LTD. (Seoul KR)	X			X						Nuclear transfer									
US20120093879	pending	/19/2012	CARDIAC STEM CELLS AND USES OF SAME IN CARDIAC REPAIR	UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA (Rome IT)	X		X				Cardiac cells			Form cardiospheres from adult cardiac tissue									
US20120095188	pending	/19/2012	ESTABLISHMENT OF INDUCED PLURIPOTENT STEM CELL USING CELL-PERMEABLE REPROGRAMMING TRANSCRIPTION FACTOR FOR CUSTOMIZED STEM CELL	PROCELL THERAPEUTICS INC. (Seoul KR)			X	X						Fusion protein with reprogramming factors	X	X	X					X	
US20120100569	pending	/26/2012	SUPERCHARGED PROTEINS FOR CELL PENETRATION		X			X						Method for reprogramming using modified reprogramming factors						X			
US20120100615	pending	/26/2012	CELL FATE CONVERSION OF DIFFERENTIATED SOMATIC CELLS INTO GLIAL CELLS	CASE WESTERN RESERVE UNIVERSITY (Cle eland OH US)	X			X						Make somatic cells into glial cells with Sox10 Nkx6.2 Olig2									
US20120115225	pending	5/10/2012	REPROGRAMMING OF SOMATIC CELLS WITH PURIFIED PROTEINS		X			X						Reprogram with histone deactylase inhibitors	X	X	X					X	
US20120121 5 8	pending	5/17/2012	PRODUCTION OF REPROGRAMMED PLURIPOTENT CELLS		X			X			Stro-1 multipotent cells				X	X	X					X	

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US20120122221	pending	5/17/2012	METHOD FOR PRODUCING CELL MEDICINE	NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Kumamoto JP)	X			X		Produce phagocytes				Create phagocytes that express antibody against beta-amyloid from iPS cells								X	
US20120128655	pending	5/2 /2012	INDUCED PLURIPOTENT STEM CELLS	The McLean Hospital Corporation	X			X						Use HIV/TAT protein fused with reprogramming factors	X								
US2012012922	pending	5/2 /2012	Method and apparatus for changing one type of cell into another type of cell		X			X						Use electric/magnetic field to mo e RNA from donor cell to host cell and transform host cells.									
US20120129262	pending	5/2 /2012	Methods of Modifying Transcriptional Regulatory Networks in Stem Cells		X		X	X						Make progenitor cells from iPS cells	X							X	
US20120129835	pending	5/2 /2012	SCHIZOPHRENIA METHODS AND COMPOSITIONS	SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla CA US)	X				X					Use iPS cell-deri ed neuronal cells that exhibit a marker and test compounds to reduce marker le els									
US2012013 966	pending	5/31/2012	EMBRYONIC STEM CELL SPECIFIC MICRORNAS PROMOTE INDUCED PLURIPOTENCY	The Regents of the Uni ersity of California (Oakland CA US)	X			X						Use miRNA to reprogram cells	X	X						X	
US20120135522	pending	5/31/2012	METHODS OF MODULATING CELL REGULATION BY INHIBITING P53		X			X						Use small molecule inhibitor of p53 to make PS cells								X	
US20120135525	pending	5/31/2012	REPROGRAMMING T CELLS AND HEMATOPOIETIC CELLS		X			X		T cells/CD3				Make iPS cells from T cells	X							X	
US201201 1 1	pending	6/7/2012	Methods and Compositions for Treatment of Muscular Dystrophy	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	X			X						Make muscle cells from fibroblasts using expression cassettes that integrate into chromosome and express muscle protein							X		
US201201 209	pending	6/7/2012	GENERATING IPS CELLS BY PROTEIN TRANSDUCTION OF RECOMBINANT POTENCY-	LD Biopharma Inc. (San Diego CA US)	X			X						Produce reprogramming factors from bacter a and introduce into somatic cells	X	X	X					X	
US20120156138	pending	6/21/2012	Methods and Compositions for the Treatment of Medical Conditions In ol ing Cellular Reprogramming				X							Nucle c acid therapeutic that inhibits gene product production (highly modified)								X	
US2012015668	pending	6/21/2012	SELECTION METHOD OF INDUCED PLURIPOTENT STEM CELLS	KYOTO UNIVERSITY (Kyoto JP)	X			X						Select iPS cell in which expression of reprogramming factor is repressed measure RNA	X	X	X						
US20120156778	pending	6/21/2012	METHOD FOR EFFICIENT PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS UTILIZING CELLS DERIVED FROM ORAL MUCOSA	OSAKA UNIVERSITY (Osaka JP)	X			X		gingi al fibroblasts	oral mucosa			Reprogram oral mucosal fibroblasts into iPS cells with factors.	X	X						X	
US20120171722	pending	7/5/2012	PERSONALIZED PRODUCTION OF BIOLOGICS AND METHOD FOR REPROGRAMMING SOMATIC	AVM Biotechnology LLC (Seattle WA US)	X			X						Transfect a synthetic or endogenous pluripotent stem cell wi h genes to induce differentiation.								X	
US20120171771	pending	7/5/2012	MODIFIED IPS CELLS HAVING A MUTANT FORM OF A HUMAN IMMUNODEFICIENCY VIRUS (HIV) CELLULAR ENTRY GENE	CELLULAR DYNAMICS INTERNATIONAL INC. (Madison WI US)	X		X	X						iPS cell with mutant HIV cellular entry gene solated hematopoietic cells deri ed from the iPS cell								X	
US20120178166	pending	7/12/2012	SIMPLIFIED BASIC MEDIA FOR HUMAN PLURIPOTENT CELL CULTURE		X									Medium for proliferating stem cells									
US2012018 035	pending	7/19/2012	Methods and Compositions For Reprogramming Cells		X			X			Muscle (cardiac skeletal smooth muscle)			Use extract from myoblasts plus other reprogramming agents to reprogram cells into muscle cells.									
US20120189596	pending	7/26/2012	NUCLEAR RECEPTOR AND MUTANT THEREOF AND THE USE OF THE SAME IN THE REPROGRAMMING OF CELLS	Agency for Science Technology and Research (Connexis SG)	X			X						Introduce a nuclear receptor along wi h reprogramming factors to make iPS cells	X	X	X					X	
US20120202291	pending	8/9/2012	SIMPLIFIED BASIC MEDIA FOR HUMAN PLURIPOTENT CELL CULTURE		X									Medium for proliferating stem cells									
US20120207723	pending	8/16/2012	COMPOSITIONS AND METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS		X			X						Use nucleic acid hat an agonizes function of miR-3 and reprogramming factors to make iPS cells	X	X	X						
US20120202077	pending	8/16/2012	REPROGRAMMING COMPOSITIONS AND METHODS OF USING THE SAME		X	X	X	X						Uses repressors to modulate cell potency (increase or decrease) repressors can be nucleic acids proteins antibodies and others.	X	X	X					X	
US20120208232	pending	8/16/2012	Cell-Free Synthesis of Acti e Reprogramming Transcription Factors		X			X						Method of synthesizing reprogramming factors in cell-free reaction (fusion proteins)	X	X	X						
US20120213738	pending	8/23/2012	Cardiac Repair By Reprogramming of Cardiac Fibroblasts Into Cardiomyocytes		X	X				cardiac fibroblasts	heart	X		Method for reprogramming cardiac fibroblasts using combinations of Tbx5 Mef2C Gata Hand2 and mycoardin				X		X	X	X	
US201202137 6	pending	8/23/2012	METHOD AND COMPOUNDS FOR GENERATION OF IPSCs		X			X						Methods for making iPS cells using reprogramming factors and an agent that antagonizes a cell-specific gene or upregulates a reprogramming factor also methods for screening for such compounds.	X	X	X					X	
US2012021 236	pending	8/23/2012	GENERATING INDUCED PLURIPOTENT STEM CELLS AND PROGENITOR CELLS FROM FIBROBLASTS	MCMASTER UNIVERSITY (Hamilton ON CA)	X			X		fibroblasts	skin	X		Treat fibroblasts with POU domain-containing gene/protein (Oct) and additional cytokines cells do not become pluripotent only become neural stem cells etc.	X			X			X		
US2012021 2 0	pending	8/23/2012	VECTORS FOR GENERATING PLURIPOTENT STEM CELLS AND METHODS OF PRODUCING PLURIPOTENT STEM CELLS USING THE SAME	NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Tokyo JP)	X		X	X						Sendai irus loaded with reprogramming factors cells reprogrammed with Sendai irus methods of making	X	X	X						
US20120220030	pending	8/30/2012	Enhanced Efficiency of Induced Pluripotent Stem Cell Generation from Human Somatic Cells		X			X		fibroblasts	skin			Enrich fibroblasts that express a pluripotency marker (SSEA3) and transform wi h reprogramming factors	X	X	X					X	
US20120222003	pending	8/30/2012	Methods for Reprogramming Cells and Uses Thereof	New World Laboratories Inc. (La al CA)	X			X						Method of changing cell from one phenotype to ano her (ES cell phenotype is not made neural stem cells claimed)								X	
US20120269782	pending	10/25/2012	MATERIALS AND METHODS FOR GENERATING PLURIPOTENT STEM CELLS	Sino-American United (Shanghai) Biotechnology Institute Co. Ltd. (Shanghai CN) Sino-American iCELL (Shanghai) Biotechnology Co. Ltd. (Shanghai CN)	X			X				X		Uses amniotic ce l feeder layer to reprogram somatic cells									
US20120276215	pending	11/1/2012	Therapeutic Conditioned Media		X		X	X				X		Method of making a conditioned medium from stem cells exposed to a stressor treating diseases with conditioned medium.									
US20120276527	pending	11/1/2012	GENE RECOMBINATION SCREENING METHODS		X				X					Methods for identifying recombination e ent in cells treated with reprogramming genes uses inducible marker FMDV 2A	X	X	X					X	
US20120276636	pending	11/1/2012	METHOD FOR IMPROVING INDUCED PLURIPOTENT STEM CELL GENERATION EFFICIENCY	KYOTO UNIVERSITY (Kyoto JP)	X			X						Uses c-myc ariants to increase iPS cell production efficiency			X					X	

P bl t N b	t t	P bl t D t	T tl	/ l t N	I t	I	C t	M th f making	U / t	C ll t	T f	Th	D	th N t	OCT	Klf	M	C t k	C ll Cl		h		t t ff f b
US20120282229	pending	11/8/2012	NON-VIRAL DELIVERY OF TRANSCRIPTION FACTORS THAT REPROGRAM HUMAN SOMATIC CELLS INTO A STEM CELL-LIKE STATE		X			X						Using non- iral transfection to reprogram and determining that more than 5% of the iPS cells ha e a specific marker.	X	X	X					X	
US20120288936	pending	11/15/2012	METHODS FOR REPROGRAMMING CELLS AND USES THEREOF	New World Laboratories Inc. (La al CA)	X			X						Method of changing cell from one phenotype to ano her (ES cell phenotype is not made neural stem cells claimed)								X	
US6753 57	expired	6/22/200	Nuclear reprogramming using cytoplasmic extract	Tranxenogen (Shrewsbury MA)																			
US8298825	pending	10/30/2012	TGF-beta receptor inhibitors to enhance	The General Hospital Corporation (B M US)	X			X						Uses TGF-beta inhibitor with Oct Sox M PS ll	X		X	X				X	